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In this study we report the clinical features of 32 patients with gamma aminobutyric acid B receptor (GABABR) antibodies, identify
additional autoantibodies in patients with anti-GABABR encephalitis that mark the presence of an underlying small cell lung
carcinoma and optimize laboratory methods for the detection of GABABR antibodies. Patients (n = 3225) were tested for the
presence of GABABR antibodies using cell-based assay, immunohistochemistry and live hippocampal neurons. Clinical data were
obtained retrospectively. Potassium channel tetramerization domain-containing (KCTD)16 antibodies were identiﬁed by immuno-
precipitation, mass spectrometry analysis and cell-based assays. KCTD16 antibodies were identiﬁed in 23/32 patients with anti-
GABABR encephalitis, and in 1/26 patients with small cell lung carcinoma and Hu antibodies, but not in 329 healthy subjects and
disease controls. Of the anti-GABABR encephalitis patients that were screened sufﬁciently, 18/19 (95%) patients with KCTD16
antibodies had a tumour versus 3/9 (33%) anti-GABABR encephalitis patients without KCTD16 antibodies (P = 0.001). In most
cases this was a small cell lung carcinoma. Patients had cognitive or behavioural changes (97%) and prominent seizures (90%).
Thirteen patients developed a refractory status epilepticus with intensive care unit admittance (42%). Strikingly, 4/32 patients had
a rapidly progressive dementia. The addition of KCTD16 to the GABABR cell-based assay improved sensitivity of the in-house
ﬁxed cell-based assay, without loss of speciﬁcity. Twenty-two of 26 patients improved (partially) to immunotherapy or chemo-
therapy. Anti-GABABR encephalitis is a limbic encephalitis with prominent, severe seizures, but patients can also present with
rapidly progressive dementia. The co-occurrence of KCTD16 antibodies points towards a paraneoplastic origin. The addition of
KCTD16 improves the sensitivity of the cell-based assay.
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Introduction
Autoimmune encephalitis is a group of severe neurological
disorders, some of which are associated with pathogenic
autoantibodies directed at neuronal membrane proteins
(Graus et al., 2016), including the metabotropic gamma
aminobutyric acid B receptor (GABABR) (Lancaster et al.,
2010). The majority of patients with anti-GABABR en-
cephalitis present with limbic encephalitis with prominent
seizures. Around 50% of the patients have an underlying
small cell lung carcinoma (SCLC). Nearly all patients re-
spond, completely or partially, to immunotherapy or a
combination of immunotherapy and tumour treatment
(Lancaster et al., 2010; Hoftberger et al., 2013; Jeffery
et al., 2013; Dogan Onugoren et al., 2015; Chen et al.,
2017), stressing the importance of early diagnosis and
treatment.
Diagnostic laboratories currently test the presence of
GABABR antibodies in serum or CSF with a (commercial
or in-house) ﬁxed cell-based assay (CBA) in which both
GABAB1 and GABAB2 subunits are expressed. Sensitivity
of an in-house developed ﬁxed CBA was reported to be
100% for CSF and 67–80% for serum (Hoftberger
et al., 2013). Alternatively, a live CBA, in which the sur-
face of living transfected cells is stained with patient anti-
bodies, can be used (own observation). However, live
CBAs cannot be stored for later use and can therefore
not be commercialized for widespread use. In some stu-
dies, additional immunohistochemistry of rat brain or im-
munocytochemistry of live hippocampal neurons in
culture is used for conﬁrmation of ﬁxed CBA (Gresa-
Arribas et al., 2014).
In this study we: (i) provide a detailed description of the
clinical and laboratory ﬁndings of 32 patients with anti-
GABABR encephalitis and show that besides limbic enceph-
alitis anti-GABABR encephalitis can also present with a
rapidly progressive dementia; (ii) present a novel autoanti-
body directed at the intracellular GABABR accessory pro-
tein potassium channel tetramerization domain containing
16 (KCTD16), which points towards a paraneoplastic
origin; and (iii) evaluate the different laboratory methods
that are available for the detection of GABABR antibodies
and show that the in-house ﬁxed GABABR-CBA can be
improved by the addition of KCTD16.
Materials and methods
Patient inclusion
Samples from patients (n = 3225) clinically suspected to have
immune-mediated encephalitis were tested prospectively (May
2011 to Aug 2018) by routine diagnostic testing with immu-
nohistochemistry and commercial CBA. Two hundred and
eighty-two samples, collected for diagnostic testing of onco-
neuronal antibodies prior to the identiﬁcation of GABABR as
an autoantigen (2000–2010), were tested retrospectively with
immunohistochemistry and in-house ﬁxed CBA. Lastly, in a
cohort of 384 patients with clinical suspicion of Creutzfeldt-
Jakob disease, 22 patients were retrospectively diagnosed with
autoimmune encephalitis by a neuropathologist (Maat et al.,
2015). These 22 CSF samples were subsequently tested with
immunohistochemistry and in-house ﬁxed CBA. All diagnostic
tests were carried out by the Erasmus MC University Medical
Center (Rotterdam, The Netherlands), the Dutch national re-
ferral centre for paraneoplastic neurological syndromes and
autoimmune encephalitis. This study was approved by the in-
stitutional review board and informed consent was obtained
from patients or their relatives.
The control subjects (n = 329) included plasma or serum
from 46 anonymous healthy blood bank donors, 13 rheuma-
toid factor positive patients, 50 patients with SCLC without
neurological symptoms (13 with limited disease, 31 with ex-
tensive disease, six with unknown disease grading) (Titulaer
et al., 2009), 26 patients with Hu syndrome and SCLC, 21
patients with Lambert-Eaton myasthenic syndrome (LEMS),
voltage gated calcium channels (VGCC) antibodies and
SCLC, 50 patients with amyotrophic lateral sclerosis
(Huisman et al., 2015) and 123 patients clinically suspected
of autoimmune encephalitis.
Clinical description
Clinical information was obtained retrospectively from medical
records and telephone interviews with patients, relatives or
treating physicians. Reduced consciousness was included as a
symptom if not caused by a status epilepticus or induced by
medication. We included the results of the ﬁrst MRI, EEG and
CSF examination carried out after disease onset. The number
of antiepileptic drugs includes all medication known to control
seizures that were administered (according to clinical letters),
including intravenous drugs during intensive care unit (ICU)
admittance. Seizure types were classiﬁed according to the
International League Against Epilepsy Seizure Classiﬁcation,
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2016 (Fisher et al., 2017). Severity of clinical symptoms were
scored according to the modiﬁed Rankin scale (mRS) (van
Swieten et al., 1988). Treatment response was deﬁned as a
decrease of at least one point in mRS after immunotherapy.
Patients were classiﬁed as having limbic encephalitis when
the criteria were met as described in Graus et al. (2016).
Rapidly progressive dementia was scored using the
NINCDS-ADRDA classiﬁcation (McKhann et al., 2011).
Dementia criteria needed to be met within 6 months after
the appearance of the ﬁrst cognitive symptom or the patient
had died within 2 years after the appearance of the ﬁrst
cognitive symptom.
Statistical analysis
Incidence rate was calculated with 95% conﬁdence intervals
(CI), using the number of patients identiﬁed prospectively in
2015–2017, assuming a Poisson distribution, using available
Dutch population data (statline.cbs.nl/statweb/). Statistical
analysis was performed using IBM SPSS Statistics 21 and
GraphPad Prism 6.0. The following statistical tests were used
when appropriate: Fisher’s exact test, Fisher-Freeman-Halton
test, Mann-Whitney U-test, and Wilcoxon signed rank test.
Because of the exploratory nature of the study, P-values be-
tween 0.01 and 0.05 should be considered with caution.
Laboratory procedures for diagnostic
tests
Immunohistochemistry was carried out as previously described
(Ances et al., 2005). Brieﬂy, rat brains were ﬁxed with paraf-
ormaldehyde (PFA), cryoprotected, snap frozen and cut into
sagittal sections. Sections were incubated with patients’ serum
(1:200) or CSF (1:2). The staining was visualized with diami-
nobenzidine and slides were counterstained with haematoxylin.
Antigen retrieval using sodium citrate (pH 6) of parafﬁn
embedded SCLC tissue samples was carried out prior to stain-
ing with rabbit anti-KCTD16 (1:200) (Sigma Aldrich).
Neuronal cultures and staining were performed essentially as
previously described (Kaech and Banker, 2006; Hughes et al.,
2010). In short, living hippocampal neurons of at least 14 days
in vitro were incubated with patients’ serum (1:50) or CSF
(1:2) and were subsequently ﬁxed and stained with a ﬂuores-
cently-labelled secondary antibody.
Commercial CBA (Euroimmun) was used according to the
manufacturer’s recommendations. In short, human embryonic
kidney (HEK) cells were co-transfected with unlabelled
GABAB1 and GABAB2 and stained with patient serum (1:10)
or CSF (undiluted). For in-house CBAs HEK cells were trans-
fected with GFP-GABAB1 (kind gift from Dr Lily Jan, UCSF,
San Francisco) and GABAB2 (RN214644, OriGene) with or
without co-transfection of FLAG-KCTD16, KCTD12 or
KCTD8 (kind gift from Dr Martin Gassmann, University of
Basel, Basel) and were stained with patient serum (1:40) or
CSF (1:2). The presence of KCTD antibodies was determined
by ﬁxed CBA with HEK cells transfected with the individual
KCTD subunits. Titrations were performed using serial dilu-
tions on ﬁxed CBA. CBAs of serum and CSF, with and with-
out co-transfection of KCTD16, were stained and scored in the
same batch. For live CBA incubation with the patient sample
(serum 1:40, CSF 1:2) was performed in culturing medium
prior to ﬁxation. In addition, the samples were tested by the
diagnostic immunology laboratory at Erasmus MC University
Medical Center for the presence of a panel of classic paraneo-
plastic antibodies (anti-Hu, Yo, Ri, Ma1, Ma2, Tr, amphiphy-
sin, VGCC and CV2) and anti-neuronal surface antibodies
(anti-NMDAR, AMPAR, GABABR, LGI1 and Caspr2).
Mass spectrometry
Immunoprecipitation and mass spectrometry analysis were car-
ried out as described previously (de Graaff et al., 2012; van
Coevorden-Hameete et al., 2015). In short, protein was ex-
tracted from adult rat brains and incubated overnight with
10 ml of serum. After 16 h, protA/G Sepharose beads (GE
Healthcare Life Sciences) were added. The beads were
washed, boiled and supernatant was loaded on a 4–12%
Bis-Tris gel (Invitrogen) and sent for mass spectrometry
analysis.
Microscopy
Immunohistochemistries were scored visually on an Olympus
BX50F. CBAs and live hippocampal neurons were scored visu-
ally by two independent observers using a Nikon eclipse 80i
upright microscope. Confocal images were acquired with a
Zeiss LSM 700 using the 40 and 63 (oil) objectives.
Images were processed using ImageJ.
Data availability
Any data not published within this article are available at the
Erasmus MC University Medical Center. Patient-related data
will be shared upon request from any qualiﬁed investigator,
maintaining anonymization of the individual patients.
Results
KCTD16 antibodies are associated
with an underlying SCLC
Thirty-two patients with anti-GABABR encephalitis were
identiﬁed, of whom 18 were diagnosed prospectively and
nine retrospectively. In the ﬁve remaining patients, immu-
nohistochemistry showed neuropil staining and live neu-
rons showed surface labelling, but in-house GABABR-
CBA was initially scored negative (before optimization of
the assays). In those patients antibodies to the GABABR
were detected using immunoprecipitation and mass spec-
trometry analysis. Next to the GABABR subunits GABAB1
and GABAB2, which conﬁrmed the presence of GABABR
antibodies in these samples, in four of ﬁve patients the
intracellular GABABR-accessory protein KCTD8,
KCTD12 or KCTD16 were pulled down (Supplementary
Table 1). The presence of KCTD8, KCTD12 or KCTD16
was conﬁrmed with KCTD-only ﬁxed CBAs
(Supplementary Table 2 and Supplementary Fig. 1). A sub-
group of 23/32 (72%) anti-GABABR encephalitis patients
had KCTD16 antibodies. These antibodies were found in 1
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of 26 (4%) patients with SCLC and anti-Hu syndrome,
whereas 329 healthy and other disease control samples
(including 50 patients with SCLC without PNS, and 21
patients with SCLC, LEMS and VGCC antibodies) tested
negative. Anti-GABABR encephalitis patients with KCTD16
antibodies had an underlying tumour more frequently. Of
28 patients who underwent sufﬁcient tumour screening
(either CT thorax and abdomen or FDG-PET-CT)
(Titulaer et al., 2011b), 18 of 19 patients with KCTD16
and three of nine patients without KCTD16 antibodies had
an underlying tumour (P = 0.001) (Fig. 1A). Patients with
KCTD16 antibodies had signiﬁcantly higher anti-GABABR
titres in CSF compared to patients without KCTD16 anti-
bodies (P = 0.01) (Fig. 1B), and tended to have a status
epilepticus more frequently for which admission to the
ICU was required (P = 0.045) (Fig. 1C). No other factors
(anti-GABAB titres in serum, maximum mRS during disease
and response to immuno- and/or chemotherapy) differed
signiﬁcantly between patients with or without KCTD16
antibodies (Fig. 1D and E). SCLC biopsy tissue from a
patient with KCTD16 antibodies expressed KCTD16,
whereas normal lung tissue (Fig. 1F) and SCLC tissue
from a patient without KCTD16 antibodies did not (data
not shown).
Patients and clinical phenotype
The characteristics of all patients are summarized in Table
1. The detailed clinical information for individual patients
can be found in Supplementary Tables 3 and 4. Sixteen
patients were male (50%). The median age at disease
onset was 66 years. Incidence of anti-GABABR encephalitis
(calculated from January 2015 to December 2017) was
0.26/1 000 000 inhabitants/year (95% CI 0.14–0.44).
Limbic encephalitis was the main clinical syndrome in
most patients (27/32; 84%). Of the ﬁve remaining patients
one only had seizures and four (13%) had a rapidly pro-
gressive dementia. All four rapidly progressive dementia
patients presented with a subacute cognitive decline and
hallucinations/psychosis (Table 2). Two patients had myo-
clonia and/or cerebellar/pyramidal disturbance of move-
ment. Creutzfeldt-Jakob disease was seriously considered
in all four patients, and one patient fulﬁlled criteria for
probable Creutzfeldt-Jakob disease, according to the CDC
Diagnostic Criteria for Creutzfeldt-Jakob Disease, 2010
(https://www.cdc.gov/prions/cjd/index.html). Overall, most
patients initially presented with seizures (53%), while the
others had subacute cognitive decline or behavioural
changes. None of these 15 patients were initially considered
to have a primary psychiatric disorder. In all 15 patients
there was a subacute onset of severe cognitive symptoms or
behavioural disorders. Thirteen were directly referred to a
neurologist (after visiting the emergency room or outpatient
clinic), while two patients were ﬁrst admitted to the depart-
ment of internal medicine (one with hypertension and a
cognitive disorder, and one with pneumonia and signs of
delirium). During the disease course 31 of 32 patients
(97%) developed cognitive or behavioural problems.
Nearly all patients (90%) experienced seizures. In all
cases seizures were generalized, in 15% these were clear
focal to bilateral tonic clonic seizures. In addition, eight
patients experienced focal seizures, ﬁve of which with im-
paired awareness. In ﬁve cases the type of seizures was not
described. Often the seizures were refractory to antiepilep-
tic drugs. Thirteen patients (42%) developed a refractory
status epilepticus for which admittance to the ICU was
required. Additional symptoms that occurred frequently
were psychosis/hallucinations (32%), language/speech
problems (26%), reduced consciousness (23%) and head-
ache/vomiting (19%). The median mRS was 4 [interquartile
range (IQR): 3–5; range: 2–5] at maximum disease severity.
There were no differences between non-tumour (n = 7) and
tumour patients (n = 21) and speciﬁc clinical features [seiz-
ures presenting symptom, status epilepticus, maximum
mRS (pretreatment), best mRS (post-treatment)], although
the power was limited due to the sample size (Table 3).
Ancillary testing
The detailed results for ancillary testing from individual
patients can be found in Supplementary Table 3. CSF
analysis was carried out in 30 patients, and was abnormal
in 29 (97%). The ﬁndings mainly included mild pleiocy-
tosis (76%) and increased protein level (36%). Increased
IgG index and/or oligoclonal bands were reported in 9 of
11 patients, but were not determined in most patients.
Initial MRIs were obtained in 29 patients and were ab-
normal in 45% of the cases, most frequently T2/FLAIR-
hyperintensities of the mesiotemporal lobe (11/29; four
unilateral and seven bilateral), one patient had atrophy
of the mesiotemporal lobe and one patient had mesiotem-
poral hypointensity. Initial EEG results showed focal
slowing (76%) often in combination with epileptic dis-
charges (44%).
CSF analysis was available in three of four rapidly pro-
gressive dementia cases and showed a mild pleocytosis in
all cases, often accompanied by oligoclonal bands or an
elevated IgG index. In two of four patients, 14–3–3 was
present in CSF and tau was very high (with relatively
normal phospho-tau, ratio4 40). In the patient that
lacked 14–3–3 protein in CSF, the EEG showed triphasic
complexes typical of Creutzfeldt-Jakob disease. In the other
cases the EEG was either normal or showed an aspeciﬁc
encephalopathy. Together with the clinical ﬁndings one pa-
tient met the criteria for ‘probable Creutzfeldt-Jakob
disease’.
In two of four patients with rapidly progressive dementia
diagnosis of anti-GABABR encephalitis was made post-
mortem. In the remaining two, MRI and CSF abnormalities
initiated the search for anti-neuronal autoantibodies and a
possible underlying tumour, leading to the diagnosis of
autoimmune encephalitis.
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Tumour association and response to
treatment
Tumour screening with (FDG-PET) CT of thorax and ab-
domen was carried out in 28 patients, of whom 16 (57%)
had an underlying SCLC, one patient had a small cell car-
cinoma of the bladder, and four (14%) had disseminated
disease of a primary tumour of unknown type (in those
patients no material for pathological examination could
be obtained). Besides GABABR antibodies, two patients
Figure 1 KCTD16 antibodies are associated with an underlying tumour. (A) Bar diagram depicting percentages of patients with or
without an underlying tumour. Patients with KCTD16 antibodies more frequently have an underlying tumour. Fisher exact test, P = 0.001. (B)
Scatterplot depicting serum and CSF anti-GABABR titres of patients with or without KCTD16 antibodies; lines indicate median values. GABABR
antibody titres in serum do not differ between patients with or without KCTD16 antibodies, whereas antibody titres in CSF are significantly
higher in patients with KCT16 antibodies. Mann-Whitney test, P = 0.24 (serum), P = 0.01 (CSF). (C) Bar diagram depicting percentages of patients
with a status epilepticus. Status epilepticus tended to occur more frequently in patients with KCTD16 antibodies when compared to patients
without KCTD16 antibodies. Fisher exact test, P = 0.045 (P-values between 0.01 and 0.05 should be considered with caution). (D) Scatterplot
depicting mRS at disease maximum, lines indicate median values. Maximum disease severity does not differ between patients with or without
KCTD16 antibodies. Mann-Whitney test, P = 0.59. (E) Scatterplot depicting minimal mRS after treatment, lines indicate median values. Response
to treatment does not differ between patients with or without KCTD16 antibodies. Mann-Whitney test, P = 0.20. (F) Immunohistochemistry of
SCLC tissue from Patient 5, stained with haematoxylin and eosin (HE), normal rabbit serum and KCTD16 antibody. The image shows specific
KCTD16 expression in tumour cells, which is absent in healthy lung tissue. Staining was performed on sequential slides and images were taken in
the same area of the sample. Scale bars = 25mm.
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with an unknown tumour type had other SCLC-associated
antibodies (anti-AMPAR and anti-VGCC). Median time to
tumour diagnosis after ﬁrst contact with a physician was 6
weeks (IQR: 2–9; range: 0–62). One patient was screened
by a pulmonologist for suspected lung cancer prior to the
onset of the neurological symptoms, the other patients
were diagnosed after the onset of neurological symptoms
(96%).
Treatment data were available in 31 patients. Patients
were treated with a combination of immuno- and tumour
therapy [11/31 (35%)], immunotherapy alone [14/31
(45%)], tumour therapy alone [2/31 (6%)] or remained
untreated [4/31 (13%)]. The majority of the patients [22/
26 (85%)] responded to treatment, with a median best
mRS of 2 (IQR: 1–3; range: 1–5) after treatment. In 19/
21 patients with seizures and treatment response, seizure
freedom was reached with a median time to seizure free-
dom after immunotherapy of 6 days (IQR 0–22, range 0–
239). In 17/21 patients with cognitive symptoms and treat-
ment response, cognitive symptoms improved after im-
munotherapy, with a median of 35 days (IQR 10–104,
range 10–265). Seizure freedom was achieved faster than
cognitive improvement (n = 20; P = 0.012). In 20 patients
both cognitive improvement and seizure freedom were as-
sessed after immunotherapy. In 13 patients (65%) seizure
freedom was reached earlier than cognitive improvement,
while ﬁve patients (25%) ﬁrst showed cognitive improve-
ment. In two patients seizure freedom and cognitive im-
provement were reached simultaneously (10%).
Two patients who did not respond had a poor overall
physical condition and died shortly after immunotherapy
before effects were assessable. Four patients did not receive
treatment because of poor overall condition or because
their disease presented prior to discovery of autoimmune
encephalitis; one of these showed some improvement spon-
taneously. Two patients relapsed after 4 and 6 months,
respectively. No tumour was found at relapse either.
At last follow-up, 13 of 32 patients were still alive (median
follow-up 16 months; IQR: 8–27; range 2–109). Median
mRS at last follow-up was 2 (IQR: 2–3; range 0–4).
Median survival was 17 months (95% CI 7.80–26.20), not
different between patients with tumours (15 months, 95%
CI 11.04–18.96), or without (no median number as 450%
survived, P = 0.36; Fig. 2). The two (of seven) deceased pa-
tients without a tumour had their anti-GABABR encephalitis
diagnosis made post-mortem. One patient (Patient 26) had a
rapid progressive dementia, presumed Creutzfeldt-Jakob dis-
ease, and was not treated. He died due to neurological
Table 1 Patient characteristics (n = 32)
Male: female 16: 16
Median age of onset (IQR, range) 66 (57–75, 44–85)
Presenting symptom
Seizures 17 (53%)
Cognitive(/behavioural)a 6 (19%)
Behavioural/(cognitive) 9 (28%)
Clinical syndrome
Limbic encephalitis 27 (84%)
Rapidly progressive dementia 4 (13%)
Epilepsy 1 (3%)
Symptoms (during disease course)
Cognitive and/or behavioural 31/32 (97%)
Seizures 29/32 (90%)
Generalized 26/26 (100%)
Focal to bilateral tonic clonic 4/26 (15%)
Focal with impaired awareness 5/26 (19%)
Focal 3/26 (12%)
Hallucinations 10/31 (32%)
Language/speech 8/31 (26%)
Reduced level of consciousness 7/31 (23%)
Headache and/or vomiting 6/31 (19%)
Autonomic dysregulationb 4/31 (13%)
Focal neurological symptomsc 4/31 (13%)
Sleep disturbance 3/31 (10%)
Movement disorderd 2/31 (6%)
Cerebellar symptoms 1/31 (3%)
Super refractory status epilepticus 13/31 (42%)
Median number of AEDs (IQR, range) 2 (1–4, 0–6)
CSF (first performed, n = 30)
Pleocytosis (median, range cells/mm3) 23/30 (17, 7–195) (76%)
Elevated protein 9/25 (36%)
Normal 1/30 (3%)
MRI (first performed, n = 29)
Mesiotemporal T2/FLAIR hyperintensities 11/29 (38%)
Bilateral 7/11 (64%)
Unilateral 4/11 (36%)
Mesiotemporal atrophy 1/29 (3%)
Mesiotemporal hypointensities 1/29 (3%)
Normale 16/29 (55%)
EEG (first performed, n = 25)
Epileptic and encephalopathic 11/25 (44%)
Encephalopathic 8/25 (32%)
Epileptic 2/25 (8%)
Normal 4/25 (16%)
Tumour
SCLCf 16/32 (50%)
Small cell bladder tumour 1/32 (3%)
Tumour, unknown type 4/32 (13%)
No tumour, sufficient screening 7/32 (22%)
No tumour, insufficient screening 4/32 (13%)
Other onconeuronal antibodiesg 8/32 (25%)
Treatment
Immunotherapy 14/31 (45%)
Tumour therapy 2/31 (6%)
Immunotherapy + tumour therapy 11/31 (35%)
No treatment 4/31 (13%)
Response to treatment 22/26 (85%)
aSymptoms were scored as cognitive(/behavioural) if patients mainly had cognitive
symptoms, or as behavioural/(cognitive) if patients mainly had behavioural problems.
bBradypnoea, tachypnoea, asystolia, bradycardia.
cParesis arm, facial paresis, apraxia, gait instability.
dMyoclonus (2 ).
eTwo of eight patients with initial normal MRI developed mesiotemporal T2/FLAIR
hyperintensities later in the disease course, and one patient developed mesiotemporal
atrophy later in the disease course (five remained normal).
fFourteen of 15 tumour patients (93%) smoked or had a history of smoking (in six
patients data were not available).
gHu (2 ), VGCC (2 ), GABAAR, GAD, Sox1, Ri, AMPAR (2 ).
AED = antiepileptic drug; pleocytosis 5 5 cells/mm3; elevated protein 5 0.58 g/l.
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deterioration. The other patient (Patient 27) was treated
with methylprednisolone and intravenous immunoglobulins
for a possible autoimmune encephalitis, but had a severe
syndrome with status epilepticus, autonomic dysfunction
and respiratory failure caused by a pneumonia. ICU treat-
ment was discontinued after 1 month because of inconclu-
sive diagnosis, older age, and a history of cognitive
impairment. None of the other patients without tumour
died after this acute phase. Eight of 14 deceased patients
with tumour died of tumour progression. In the other six
patients with a tumour, the cause of death was not reported.
Three of four patients with insufﬁcient tumour screening had
died, two due to infection, while in one patient the cause of
death was not reported. In six patients no initial improve-
ment occurred prior to death of which four were not treated
with immunotherapy. Until deterioration leading to death,
the patients responded (partially), resulting in a median mRS
of 2 (IQR 2–4; range 1–5).
Addition of KCTD16 to
GABABR-CBA improves detection
The patients’ sera (n = 30) and CSF (n = 21) samples were
tested for the presence of GABABR antibodies using a set of
different laboratory techniques (Fig. 3A–C and
Supplementary Table 5). All sera and CSF samples
showed neuropil staining on immunohistochemistry
(Fig. 3A and D). All CSF samples and all but one sera
tested, labelled the surface of live hippocampal neurons
(Fig. 3B and D). Twenty-eight of 30 sera and 20/20 CSF
samples were anti-GABABR positive using live CBA
(Fig. 3C and D). With commercial CBA GABABR antibo-
dies were detected in all but one serum (97%); however,
the sensitivity of the CSF samples was 84% (16/19)
(Fig. 3D). Three of 1125 serum samples tested in routine
diagnostics were positive by commercial CBA without con-
ﬁrmation in CSF or by other laboratory tests and
Table 2 Patient characteristics of the four patients with rapidly progressive dementia
Characteristic Patient 24 Patient 26a Patient 28 Patient 31
Sex Maleb Malec Femaled Malee
Age at onset 56 77 85 72
Tumour No No No No screening
Presenting
symptom
Behavioural (/cognitive) Behavioural (/cognitive) Behavioural (/cognitive) Cognitive (/behavioural)
Symptoms during
disease course
Subacute cognitive decline,
complete loss of memory
and recognition, apraxia
and hallucinations, sleep
disturbance
Hypertension, psychotic
behaviour, cognitive decline
in days followed by cere-
bellar ataxia and aphasia
Pneumonia, 2 weeks later
confusion, visual hallucina-
tions, psychotic behaviour,
memory deficit
Acute psychosis, within
days followed by cogni-
tive decline, only later
on in disease course a
few seizures and
myoclonus
CSF 105 WBC, elevated protein,
elevated IgG index, OCB;
14-3-3 positive; tau 12880,
phospho-tau 95
18 WBC, elevated IgG index,
OCB; 14-3-3 negative, tau
and phospho-tau normal
- 15 WBC; 14-3-3 positive,
tau 2450, phospho-tau
normal
MRI Hyperintensity
mesiotemporal (bilateral)
Atrophy mesiotemporal, vas-
cular white matter lesions
Normal Hyperintensity mesiotem-
poral (unilateral)
EEG Encephalopathic Triphasic periodic complexes
and encephalopathic
- Normal
Autopsy brain - Perivascular inflammatory
infiltrates consisting of B
and T cells. Local infiltra-
tion in the hippocampus
and basal ganglia. No evi-
dence for CJD
- Perivascular lymphocyte
infiltration and gliosis left
hippocampus. No evi-
dence for CJD
Maximum mRS 4 5 4 5
Immunotherapy MP + IVIg + rituximab - MP + IVIg + rituximab +
cyclophosphamide
MP
Best mRS after
treatment
2 5 3 5
Treatment response Responded to therapy Not treated Some response to
immunotherapy
Not treated
Follow-up, months 7 1f 3 4f
aFulfilled criteria for ‘probable CJD’, but pathology refuted this diagnosis.
bSee vertical line symbol in Supplementary Tables 3–5.
cSee filled diamond in Supplementary Tables 3–5.
dSee filled hexagon in Supplementary Tables 3–5.
eSee open square in Supplementary Tables 3–5.
fDeceased.
CJD = Creutzfeldt-Jacob disease; IVIg = intravenous immunoglobulin; MP = methylprednisolone; OCB = oligoclonal bands; WBC = white blood cells.
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considered clinically irrelevant, resulting in a speciﬁcity of
99.7%. In-house ﬁxed CBA detected GABABR antibodies
in 26/30 (87%) of the sera and 18/20 (90%) of the CSF
samples. When GABAB1 and GABAB2 subunits were co-
transfected with the GABABR-accessory subunit KCTD16,
the sensitivity for serum improved to 29/30 (97%) and in
CSF to 20/20 (100%) (Fig. 3D). The addition of KCTD8 or
KCTD12 to the CBA was inferior to KCTD16 (data not
shown).
To validate the improvement of the ﬁxed CBA by the
addition of KCTD16, we performed serial dilution of all
sera and 17 CSF samples on ﬁxed CBA with and without
co-expression of KCTD16. We observed a signiﬁcant in-
crease in titres detected with the CBA with KCTD16 co-
expression (Fig. 4A–C). This effect was seen in both serum
and CSF (serum 23/29, 79%, P = 0.00008; CSF 14/17,
82%, P = 0.001). Titres had a median 8-fold increase
(IQR 2–52, range 0–800, P5 0.0001) in serum and a
median 4-fold increase in CSF (IQR 2–7, range 0–256,
P = 0.001). Fold changes in serum and CSF titres did not
differ signiﬁcantly between patients with and without
KCTD16 antibodies. Also, the addition of KCTD16 to
the ﬁxed CBA did not result in a reduction of speciﬁcity
as 193 healthy and diseased control samples tested nega-
tive. No differences were found between titres of patients
with and without underlying tumours (Fig. 4D).
Discussion
This study (i) identiﬁes GABABR antibodies in pa-
tients with rapidly progressive dementia in the absence
of seizures, in addition to the majority of patients ex-
hibiting limbic encephalitis with prominent and severe
seizures; (ii) describes a novel autoantibody directed
against the GABABR accessory protein KCTD16,
which is strongly associated with a SCLC; and (iii)
shows that the addition of KCTD16 to the ﬁxed
GABABR CBA results in improved detection of
GABABR antibodies.
Drug-resistant generalized seizures are the most promin-
ent clinical feature of anti-GABABR encephalitis. About
half of the patients required ICU admittance to control
seizures, which is more frequent than previously reported
(Lancaster et al., 2010; Hoftberger et al., 2013). Moreover,
Table 3 Clinical features comparing tumour and non-tumour patients
Tumour (n = 21) No tumour (n = 7) All (n = 28) P-value
Seizures presenting symptom 13 (62%) 3 (43%) 16 (57%) 0.42
Status epilepticus 10 (50%)a 1 (14%) 11 (41%)a 0.18
Max mRS (pretreatment) (n = 21) (n = 7) 0.86
2 3 0 3
3 7 2 9
4 3 2 5
5 8 3 11
Best mRS (post-treatment) (n = 19) (n = 6) 1.00
1 5 2 7
2 9 2 11
3 3 1 4
4 2 1 3
Deceased at last follow-up 14 (67%) 2 (29%) 16 (57%)
Survival in months, median (95% CI) 15 (11.04–18.96) na (550% deceased) 17 (7.80–26.20) 0.36
aFor one patient, status epilepticus was unknown.
na = not applicable; see Fig. 2 for Kaplan-Meier curve. Median in this instance refers to the moment where 50% of patients had died; as550% died, we are unable provide this value.
Figure 2 Kaplan Meier curve of survival comparing
tumour and non-tumour patients. Showing the data of patients
with (n = 21) and without tumours (n = 7). Median survival was 17
months (95% CI 7.80–26.20), not different between patients with
tumours (15 months, 95% CI 11.04–18.96), or without (no median
number as 450% survived, P = 0.36).
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this number probably underestimates the occurrence of
drug-resistant epilepsy, as only cases that required ICU ad-
mittance were taken into account. In contrast with anti-
GABABR limbic encephalitis with early and severe seizures,
4 of 32 patients presented with rapidly progressive demen-
tia, of whom only one developed seizures late in the disease
course. As literature on pure cognitive decline in patients
with anti-neuronal autoantibodies is sparse (Geschwind
et al., 2008; Escudero et al., 2017), many patients with
rapidly progressive dementia are not investigated for anti-
bodies. CSF abnormalities such as 14–3–3 protein, high
phospho-tau/tau ratios did not discriminate between neuro-
degenerative disease and anti-GABABR encephalitis. Clues
for autoimmune encephalitis, such as (mild) pleocytosis,
oligoclonal bands or typical MRI abnormalities might
hint towards an autoimmune aetiology, and were helpful
in three of our cases. However, as ancillary testing might be
normal and antibodies are not often thought of, patients
with this treatable cause of dementia might not be diag-
nosed in general practice and denied treatment.
The presence of KCTD16 antibodies increases the prob-
ability of a paraneoplastic origin, and the necessity to
screen more rapidly and more frequently. An underlying
tumour occurred in almost all patients with KCTD16 anti-
bodies, as opposed to three of nine patients without
KCTD16 antibodies. Two paraneoplastic anti-GABABR en-
cephalitis patients lacked KCTD16 antibodies but had
other SCLC-associated antibodies, anti-Hu and anti-
VGCC, respectively. However, these were absent in the
majority of the KCTD16-positive SCLC patients.
Therefore, anti-KCTD16 seems to have additional value
to other SCLC-associated autoantibodies, such as
Figure 3 Diagnostic tests for GABAB receptor antibodies. (A) Immunohistochemistry of adult rat brain stained with patient CSF or
control CSF. The patient CSF shows brain-wide neuropil staining, here exemplified by an image of the hippocampus. Scale bars = 500 mm. (B)
Immunocytochemistry of living rat hippocampal neurons. Labelling with the patient serum (green) results in a dot-like pattern along the neurites.
Scale bars = 10mm. (C) Live in-house CBA of HEK cells transfected with GABAB1-GFP and GABAB2 (green) and stained with patient serum or
control serum (red). The patient serum labels the surface of cells transfected with GABAB receptor. Scale bars = 20mm. (D) Bar diagram
representing the percentages of positive and negative tests for the different laboratory techniques that are used for the detection of GABAB
receptor antibodies. For one patient, CSF was not available to perform CBA, but this sample did test positive for GABAB receptor in live CBA
(Dalmau lab, Barcelona).
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anti-SOX1 (Sabater et al., 2008; Hoftberger et al., 2013),
anti-Hu (Pignolet et al., 2013) and anti-VGCC (Mason
et al., 1997), and can help in predicting a paraneoplastic
origin of autoimmune encephalitis. The presence of
KCTD16 antibodies in one patient with anti-Hu syndrome
and SCLC shows the association of anti-KCTD16 with
SCLC, also outside the context of anti-GABABR encephal-
itis. However, we could not detect staining against
KCTD16 proteins in the SCLC of one patient without
paraneoplastic neurological syndrome, as has been pub-
lished for Hu (Pignolet et al., 2013) and SOX1 (Sabater
et al., 2008). It would be of additional value to study the
expression of GABABR and KCTD16 in more SCLC of
patients without paraneoplastic neurological syndrome.
The presence of anti-KCTD16 is associated with higher
GABABR antibody titres in CSF and a more frequent severe
status epilepticus. This is likely explained by the presence of
an underlying tumour, which has also been associated with
more severe disease in anti-NMDAR encephalitis (Gresa-
Arribas et al., 2014) and LEMS (Titulaer et al., 2011a).
Neither KCTD16, nor the presence of a tumour were pre-
dictive of survival. Although shorter survival time in SCLC-
GABABR patients is expected, this was not found. Likely
explanations are the small number of idiopathic anti-
GABABR encephalitis patients, and the lack of a diagnosis
before dying, leading to no or insufﬁcient immunotherapy.
The two deceased patients without tumour died within 2
months from symptom onset, had their diagnosis made
Figure 4 Endpoint titrations with fixed cell-based assay. (A) Titration of serum of an anti-KCTD16-negative patient (red) using a fixed
CBA of HEK cells transfected with GABAB1-GFP and GABAB2 (green) with or without co-transfection of KCTD16. Staining of cells co-trans-
fected with KCTD16 can be detected up to a dilution of 1:3200, as opposed to without KCTD16 co-transfection, up to a dilution of 1:800. (B)
Serum titres detected with a fixed CBA with or without co-transfection of KCTD16. Higher serum titres are detected with the addition of
KCTD16 to the CBA. Median serum titre detected with the GABAB1/2 assay was 200 (IQR 60–1600, range 0–25 600), and with addition of
KCTD16 3200 (IQR 3200–9600, range 0–64 000; P5 0.0001). (C) CSF titres detected with or without co-transfection of KCTD16. Higher CSF
titres are detected with the addition of KCTD16 to the CBA. Median CSF titre detected with the GABAB1/2 assay was 64 (IQR 7–160, range 0–
512), and with addition of KCTD16 128 (IQR 48–512, range 4–2048; P = 0.001). (D) Serum and CSF titres detected with a fixed CBA without
KCTD16 co-transfection. Patients with an underlying tumour do not have higher titres in serum and CSF than patients without an underlying
tumour. Mann-Whitney test, serum P = 0.23, CSF P = 0.41. Symbols in B–D refer to individual patients, which are explained in greater detail in
Supplementary Tables 1 and 3–5.
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post-mortem and were offered no treatment or insufﬁcient
treatment. The other idiopathic anti-GABABR encephalitis
patients survived after the acute disease phase.
The fact that anti-KCTD16 co-occurs with SCLC sug-
gests that their formation is a result of the aberrant expres-
sion of KCTDs, by SCLC tissue. Although most patients
had both anti-KCTD and anti-GABABR antibodies, sug-
gesting aberrant expression of the GABABR-KCTD com-
plex, KCTD antibodies were not limited to anti-GABABR
encephalitis as one patient with anti-Hu syndrome and
SCLC also had these. Unlike the GABABR antibodies, the
KCTD16 antibodies are directed at an intracellular antigen
and most likely do not have pathogenic properties, al-
though this was not tested within the scope of this study.
We show that co-expression of the intracellular auxiliary
subunit KCTD16 with GABAB1 and GABAB2 in a ﬁxed
CBA improves the detection of GABABR antibodies.
Native GABABRs consist of two different core receptor
units GABAB1a/b and GABAB2. These core receptor sub-
units control receptor surface expression, axonal and den-
dritic distribution, ligand binding and G-protein coupling
(Gassmann and Bettler, 2012). In addition, the GABAB2
subunit binds homo- or heterotetrameres of cytosolic aux-
iliary proteins belonging to the KCTD family (KCTD8,
KCTD12, KCTD12b and KCTD16). The different KCTD
family members show distinct expression proﬁles in the
brain and bind to the intracellular part of GABAB2 as a
stable and obligatory part of the receptor at the cell sur-
face. The KCTDs induce desensitization of K+ currents in
response to GABABR activation in a subtype-speciﬁc
manner (Schwenk et al., 2010; Seddik et al., 2012;
Adelﬁnger et al., 2014; Turecek et al., 2014). Given the
properties of KCTD proteins, there are several possible ex-
planations for the improvement of the ﬁxed CBA by the
addition of KCTD16 (Fig. 5); GABABR antibodies are dir-
ected at a conformational epitope (Hoftberger et al., 2013)
and their binding might be suboptimal when the receptor is
lacking an integral component, such as a KCTD protein
(Fig. 5A and B) (Schwenk et al., 2010). Alternatively, the
co-expression of KCTD16 could lead to improved cluster-
ing of GABABR on the cell surface, via binding of KCTD16
to a (currently unidentiﬁed) scaffold protein (Fig. 5C). A
previous study shows that the detection of low-afﬁnity anti-
bodies to the acetylcholine receptor in myasthenia gravis
can be improved by clustering the acetylcholine receptor
in CBAs (Leite et al., 2008). Lastly, the additional
KCTD16 antibodies could be a partial explanation for
the improved detection, as with the addition of KCTD16
the ﬁxed CBA now also detects anti-KCTD16 titres.
However, patients also lacking anti-KCTD16 showed
increased titres with KCTD16 co-expression.
Importantly, the addition of KCTD16 to the ﬁxed CBA
increases sensitivity of the assay, without loss of speciﬁ-
city. Despite different optimization steps, some serum
samples remained difﬁcult to score by the in-house assay
due to high noise levels. As the addition of KCTD16 in-
creases the dilution the test can still be scored positive, the
noise level becomes smaller. The net result is an improve-
ment of the signal-to-noise ratio. With the addition of
KCTD16 the ﬁxed CBA performs as well as the live
CBA with the advantage that it could be stored and is
therefore suitable for use in many clinical diagnostic
laboratories. For CSF samples the GABABR-KCTD16
CBA performs better than the current commercial CBA.
This diminishes the chance of a missed diagnosis if only
CSF is sent for testing.
The main limitations of our study are because of its
retrospective design and the low incidence of anti-
GABABR encephalitis when compared to anti-NMDAR en-
cephalitis (Titulaer et al., 2013) or anti-LGI1 encephalitis
(van Sonderen et al., 2016). This leads to the limited avail-
ability of clinical data and the lack of a standardized treat-
ment regimen that could be evaluated. In addition, the
retrospective identiﬁcation of patients with anti-GABABR
encephalitis amongst samples collected for testing for onco-
neural antibodies could have led to biased results, as could
be the case for the higher tumour frequency in our study
when compared to previous studies (Lancaster et al., 2010;
Hoftberger et al., 2013).
Overall, our ﬁndings have three major practical implica-
tions: (i) anti-GABABR encephalitis should also be con-
sidered in patients with rapidly progressive dementia; (ii)
KCTD16 antibodies can be used in clinical practice to de-
termine the likelihood of an underlying SCLC in patients
with paraneoplastic neurological syndrome and can lead to
early tumour diagnosis and treatment; and (iii) the addition
of KCTD16 to the ﬁxed GABABR CBA increases sensitivity
without loss of speciﬁcity. Early diagnosis of anti-GABABR
encephalitis is of great importance, given the fact that most
patients respond to treatment.
Figure 5 GABAB receptor with and without KCTD16
co-expression. Schematic representation of the possible effect of
the addition of KCTD16 to the CBA. (A) GABAB1 and GABAB2
subunits expressed without co-expression of KCTD16. (B)
GABAB1 and GABAB2 subunits expressed with co-expression of
KCTD16 resulting in a conformational change in the GABAB re-
ceptor that allows for more efficient antibody binding. (C) GABAB1
and GABAB2 subunits expressed with co-expression of KCTD16
resulting in clustering of GABAB receptors via the unknown scaffold
protein ‘X’ resulting in more dense antibody labelling.
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